跳至主要内容
临床试验/NCT06430359
NCT06430359招募中不适用

Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients Treated With Chelators or Zinc Salts

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年1月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
Correlation factor

研究概览

简要总结

Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.

Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.

Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.

Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.

There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.

According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.

The study would aim to find the period of the day best correlated with 24h urinary copper excretion

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
6 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4).
  • Age ≥ 6 years and ≤70 years.
  • Patient able to perform 24h urine.
  • Current treatment with D-Pencillamine, Trientine or Zinc.
  • Non-opposition of patient and/or legal representatives for minor patients.

排除标准

  • Patients who had a change in treatment within the last 6 months before the inclusion
  • Patients who have undergone liver transplantation
  • Patients with known chronic renal failure (GFR < 30 ml/min)
  • Patients on long-term diuretic or corticosteroid therapy
  • Persons deprived of liberty by a judicial or administrative decision
  • Patient under judicial protection, unable to express consent

研究组 & 干预措施

Group 1 - DP

Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine

干预措施: urine and blood test (Diagnostic Test)

Group 2 - Trientine

Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine

干预措施: urine and blood test (Diagnostic Test)

Group 3 - ZINC

Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.

干预措施: urine and blood test (Diagnostic Test)

结局指标

主要结局

Correlation factor

时间窗: Two 24-hour urine recollection

Correlation between 24-hour urinary copper excretion and 8-hour urinary copper excretion collected between midnight and 8 am).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验